Table 2 Characteristics for cases and controls

Age (years)

66.5 ± 12.8

68.1 ± 10.8

0.01

Female sex (%)

42.4

40.8

0.52

Race (%)

 Black

6.0

4.1

0.16

 Caucasian

84.5

86.1

 Other

9.4

9.8

 BMI (kg/m²)

27.8 ± 6.3

27.4 ± 6.3

0.29

 Smoking (%)

15.5

14.1

0.41

Co-morbidities (%)

 Cardiovascular disease

57.9

58.2

0.87

 Cerebrovascular disease

17.7

16.3

0.46

 Chronic pulmonary disease

32.5

30.0

0.27

 Chronic liver disease

2.2

3.1

0.33

 Congestive heart failure

37.4

37.8

0.89

 Diabetes

57.9

53.1

0.05

 Hyperlipidemia

58.3

58.7

0.87

 Hypertension

94.8

94.1

0.52

 Malignancy

17.7

16.7

0.60

 Peripheral vascular disease

37.4

36.7

0.75

ASA daily dose

 Unexposed

50.7

49.3

0.79

 80-324 mg

35.7

37.3

 ≥ 325 mg

13.7

13.4

Other medication use (%)

 Anticoagulant

28.9

21.2

>0.001

 Antiplatelet

11.0

11.8

0.63

Laboratory data

 Albumin (g/L)

33.2 ± 6.6

33.9 ± 6.5

0.09

 eGFR (ml/min•1.73 m²)

9.0 ± 3.7

9.1 ± 4.0

0.65

 Hemoglobin (g/L)

10.2 ± 1.8

10.5 ± 1.8

0.01